Since the crosstalk between EGFR and HER2, researchers speculate that HER2 genomic gains and overexpression may be correlated with better response to EGFR-TKIs, which is supported by several study in TKIs naive NSCLC patients with positive EGFR expression [84–86]. Here, EGFR is linked to non-small cell lung carcinoma.